These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 29705790)

  • 21. The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications.
    Hou J; Zhang H; Sun B; Karin M
    J Hepatol; 2020 Jan; 72(1):167-182. PubMed ID: 31449859
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.
    Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W
    Front Immunol; 2020; 11():1037. PubMed ID: 32547550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma.
    Choi C; Yoo GS; Cho WK; Park HC
    World J Gastroenterol; 2019 May; 25(20):2416-2429. PubMed ID: 31171886
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The yin and yang of evasion and immune activation in HCC.
    Makarova-Rusher OV; Medina-Echeverz J; Duffy AG; Greten TF
    J Hepatol; 2015 Jun; 62(6):1420-9. PubMed ID: 25733155
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outlook: Immunotherapy in Gastrointestinal Carcinoma - Innovative Strategies.
    Moehler M; Göpfert K; Lenz HJ
    Oncol Res Treat; 2018; 41(5):313-315. PubMed ID: 29705792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotherapeutic treatments in hepatocellular carcinoma; achievements, challenges and future prospects.
    Roudi R; D'Angelo A; Sirico M; Sobhani N
    Int Immunopharmacol; 2021 Dec; 101(Pt A):108322. PubMed ID: 34735916
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autophagy in the "inflammation-carcinogenesis" pathway of liver and HCC immunotherapy.
    Yu S; Wang Y; Jing L; Claret FX; Li Q; Tian T; Liang X; Ruan Z; Jiang L; Yao Y; Nan K; Lv Y; Guo H
    Cancer Lett; 2017 Dec; 411():82-89. PubMed ID: 28987386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Perspectives of immunotherapy in hepatocellular carcinoma (HCC).
    Büttner N; Schmidt N; Thimme R
    Z Gastroenterol; 2016 Dec; 54(12):1334-1342. PubMed ID: 27936483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel immunotherapeutic approaches for hepatocellular carcinoma treatment.
    Busato D; Mossenta M; Baboci L; Di Cintio F; Toffoli G; Dal Bo M
    Expert Rev Clin Pharmacol; 2019 May; 12(5):453-470. PubMed ID: 30907177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives.
    Shen KY; Zhu Y; Xie SZ; Qin LX
    J Hematol Oncol; 2024 Apr; 17(1):25. PubMed ID: 38679698
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies.
    Giraud J; Chalopin D; Blanc JF; Saleh M
    Front Immunol; 2021; 12():655697. PubMed ID: 33815418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma.
    Cavalcante L; Chowdhary A; Sosman JA; Chandra S
    Am J Clin Dermatol; 2018 Oct; 19(5):657-670. PubMed ID: 29961183
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges.
    Liu X; Qin S
    Oncologist; 2019 Feb; 24(Suppl 1):S3-S10. PubMed ID: 30819826
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response.
    Keenan BP; Fong L; Kelley RK
    J Immunother Cancer; 2019 Oct; 7(1):267. PubMed ID: 31627733
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells.
    Ruf B; Heinrich B; Greten TF
    Cell Mol Immunol; 2021 Jan; 18(1):112-127. PubMed ID: 33235387
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potentiality of immunotherapy against hepatocellular carcinoma.
    Tsuchiya N; Sawada Y; Endo I; Uemura Y; Nakatsura T
    World J Gastroenterol; 2015 Sep; 21(36):10314-26. PubMed ID: 26420958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Role of Immunotherapy in a Tolerogenic Environment: Current and Future Perspectives for Hepatocellular Carcinoma.
    Montella L; Sarno F; Ambrosino A; Facchini S; D'Antò M; Laterza MM; Fasano M; Quarata E; Ranucci RAN; Altucci L; Berretta M; Facchini G
    Cells; 2021 Jul; 10(8):. PubMed ID: 34440678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunological landscape and immunotherapy of hepatocellular carcinoma.
    Prieto J; Melero I; Sangro B
    Nat Rev Gastroenterol Hepatol; 2015 Dec; 12(12):681-700. PubMed ID: 26484443
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical development of immunotherapy for prostate cancer.
    Noguchi M; Koga N; Igawa T; Itoh K
    Int J Urol; 2017 Sep; 24(9):675-680. PubMed ID: 28636142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma.
    Dai X; Guo Y; Hu Y; Bao X; Zhu X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Fang W
    Theranostics; 2021; 11(7):3489-3501. PubMed ID: 33537099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.